Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Next Science's 1-Year ROIIC % for the quarter that ended in Jun. 2025 was -542.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Next Science's 1-Year ROIIC % or its related term are showing as below:
NXSCF's 1-Year ROIIC % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.19
vs NXSCF: -542.77
Next Science (OTCPK:NXSCF) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Next Science 1-Year ROIIC % Related Terms
Next Science 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Next Science's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NXSCF vs GCAN, PTPI, GRPS: 1-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Next Science's 1-Year ROIIC % falls into.
Next Science's 1-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -10.566 (Jun. 2025) - -14.843 (Jun. 2024) )
/
( 4.322 (Jun. 2025) - 5.11 (Jun. 2024) )
=
4.277
/
-0.788
=
-542.77%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Next Science (NXSCF) has a 1-Year ROIIC % of -542.77 as of Jun. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Next Science and its competitors.
Is Next Science's 1-Year ROIIC % too high?
Next Science's current 1-Year ROIIC % is -542.77.
How does Next Science's 1-Year ROIIC % compare to GCAN and PTPI?
Next Science's 1-Year ROIIC % of -542.77 can be compared against companies in the Drug Manufacturers industry. The industry median 1-Year ROIIC % is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 2.19, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current 1-Year ROIIC % is -542.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (NXSCF) has a current 1-Year ROIIC % of -542.77. The stock's GF Value™ is $0.26, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current 1-Year ROIIC % is -542.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Next Science (NXSCF), the current 1-Year ROIIC % is -542.77 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXSCF has been successfully added to your 
